Publications & News

WilmerHale Counsels Agios Pharmaceuticals in Exclusive License Agreement with Aurigene Discovery Technologies

May 2, 2017

Agios Pharmaceuticals, Inc. and Aurigene Discovery Technologies Limited announced a global license agreement to research, develop and commercialize small molecule inhibitors of an undisclosed cancer metabolism target. Under the terms of the agreement, Agios will conduct pre-clinical studies and, if successful, fund further global research and development, as well as regulatory and commercial activities.

The WilmerHale team counseling Agios Pharmaceuticals included Steven Barrett and Mat Trachok.

Read Agios Pharmaceuticals' press release for more information.